All In Biotech

Drug Trial Radar · NCT02938520

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 631 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

631

Actual

Start

Oct 27, 2016

Primary completion

Aug 30, 2018

Study completion Dec 31, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Janssen Pharmaceuticals; GlaxoSmithKline
First posted
Oct 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B\*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week \[-20\] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) \<50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA \<50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.

Conditions

  • HIV Infections

Interventions

  • Cabotegravir (CAB) tabletDrug

    It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.

  • Rilpivirine (RPV) tabletDrug

    It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.

  • Cabotegravir - Injectable Suspension (CAB LA)Drug

    It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.

  • Rilpivirine - Injectable Suspension (RPV LA)Drug

    It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

  • ABC/DTG/3TC STR - TabletDrug

    It is a purple, biconvex, oval, tablet debossed with "572 Tri" on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.

  • DTG TabletDrug

    It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with "SV 572" on one side and "50" on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48Time frame: Week 48

Locations

108 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Camden, New Jersey

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Bellaire, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Longview, Texas

  • GSK Investigational Site

    Lynchburg, Virginia

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Bobigny, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Berlin, Germany

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.